Shih-Feng Cho1, Wan-Hsuan Wu2, Yi-Hsin Yang3, Chao-Sung Chang4. 1. Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C. Division of Hematology & Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C. 2. Division of Hematology and Oncology, E-Da Hospital, Kaohsiung, Taiwan, R.O.C. School of Medicine, I-Shou University, Kaohsiung, Taiwan, R.O.C. 3. School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C. 4. Division of Hematology and Oncology, E-Da Hospital, Kaohsiung, Taiwan, R.O.C. School of Medicine, I-Shou University, Kaohsiung, Taiwan, R.O.C. ccschang@gmail.com.
Abstract
AIM: This study aimed to evaluate the risk of second primary cancer (SPC) in patients receiving rituximab-containing chemotherapy. PATIENTS AND METHODS: A nationwide, population-based study was conducted using the National Health Insurance Database of Taiwan. Propensity score matching was performed to correct sample selection bias and logistic regression analysis was used to calculate odds ratios. RESULTS: Patients receiving rituximab-containing chemotherapy or conventional chemotherapy were enrolled. After adjustment by propensity score matching, there were 1,607 patients in each group. SPC was noted in 11 patients (0.68%) with rituximab-containing chemotherapy and in 19 patients (1.18%) with conventional chemotherapy (p=0.142). There was no significant difference in the age distribution at onset of SPC (p=0.327). Multivariate logistic regression analysis revealed rituximab-containing chemotherapy was not associated with risk of SPC (odds ratio (OR)=0.58; 95% confidence interval (CI)=0.28-1.23; p=0.157). CONCLUSION: Incorporation of rituximab into conventional anti-lymphoma chemotherapy did not increase the risk of SPC in patients with B-cell non-Hodgkin lymphoma (NHL). Copyright
AIM: This study aimed to evaluate the risk of second primary cancer (SPC) in patients receiving rituximab-containing chemotherapy. PATIENTS AND METHODS: A nationwide, population-based study was conducted using the National Health Insurance Database of Taiwan. Propensity score matching was performed to correct sample selection bias and logistic regression analysis was used to calculate odds ratios. RESULTS:Patients receiving rituximab-containing chemotherapy or conventional chemotherapy were enrolled. After adjustment by propensity score matching, there were 1,607 patients in each group. SPC was noted in 11 patients (0.68%) with rituximab-containing chemotherapy and in 19 patients (1.18%) with conventional chemotherapy (p=0.142). There was no significant difference in the age distribution at onset of SPC (p=0.327). Multivariate logistic regression analysis revealed rituximab-containing chemotherapy was not associated with risk of SPC (odds ratio (OR)=0.58; 95% confidence interval (CI)=0.28-1.23; p=0.157). CONCLUSION: Incorporation of rituximab into conventional anti-lymphoma chemotherapy did not increase the risk of SPC in patients with B-cell non-Hodgkin lymphoma (NHL). Copyright
Authors: Alice Bonanni; Marta Calatroni; Matteo D'Alessandro; Sara Signa; Enrica Bertelli; Michela Cioni; Eddi Di Marco; Roberto Biassoni; Gianluca Caridi; Giulia Ingrasciotta; Roberta Bertelli; Armando Di Donato; Maurizio Bruschi; Alberto Canepa; Giorgio Piaggio; Pietro Ravani; Gian Marco Ghiggeri Journal: Br J Clin Pharmacol Date: 2018-03-25 Impact factor: 4.335
Authors: Andrea Angioi; Nicola Lepori; Ana Coloma López; Sanjeev Sethi; Fernando C Fervenza; Antonello Pani Journal: J Nephrol Date: 2017-09-05 Impact factor: 3.902
Authors: Li Tao; Christina A Clarke; Aaron S Rosenberg; Ranjana H Advani; Brian A Jonas; Christopher R Flowers; Theresa H M Keegan Journal: Br J Haematol Date: 2017-05-25 Impact factor: 8.615